Meet Pharmidex at KTN 2016
June 14, 2016

Collaboration opportunities in regenerative medicine

Pharmdiex will be attending the Innvoate UK KTN 2016 meeting focused on New Collaboration Opportunities in Regenerative Medicine.

The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event focussing on new unmet clinical needs, latest developments in regulatory environment and clinical adoption. Following recent developments and the UK’s Regenerative Medicine Expert Group report recommendations, this event will bring together the UK regenerative medicine communities involving industrialists, academics and clinicians from a number of clinical specialities.


The UK is leading the field in the development of cell and gene therapies. The regulatory system now has a number of mechanisms to accelerate the progress of promising therapies including EAMS and the proposed new PRIME scheme. However, practical challenges still exist to the clinical adoption of these new therapies and getting them to patients, including generating sufficient clinical data, achieving reimbursement and embedding therapies in existing or new clinical pathways).


Leading clinicians and experts from a number of organisations will be presenting at this event. Directors and managers from major funding organisations, e.g. Innovate UK, Research Councils, relevant charities will also be invited to support this event.


The main aims of this event are as follows;


  • To discuss challenges affecting clinical adoption of cell and gene-based therapies.
  • Facilitate new clinician/industry collaborations in a number of areas of clinical specialities.
  • Identify barriers to innovation and commercialisation.
  • Review current funding opportunities and identify funding gaps.
  • Provide networking opportunities to identify collaborating partners.
  • Review supporting mechanisms available to accelerate innovation and commercialisation through KTN and partners Innovate UK, Cell and Gene Therapy Catapult organisations.
  • Review current pre-clinical and clinical trials and identify best practice to accelerate regulatory approvals


For more information please see the following link: https://www.eventbrite.co.uk/e/new-collaboration-opportunities-in-regenerative-medicine-tickets-24454460951

May 20, 2026
We are delighted to announce the promotion of Dr. Martin Barrett to Chief Business Officer at Pharmidex . Martin brings more than 23 years of experience across the pharmaceutical and drug discovery sectors, combining deep scientific expertise with strategic commercial leadership. Throughout his career, he has played a key role in advancing translational science, building strategic partnerships and supporting innovative drug development programmes. In his new role, Martin will help drive Pharmidex’s continued growth, strengthen collaborations, and expand our capabilities across preclinical pharmacology, toxicology, translational science, and clinical development support. Congratulations to Martin on this well-deserved promotion. We look forward to the continued impact of his leadership across Pharmidex and the wider drug discovery community.
May 19, 2026
Pharmidex is pleased to announce that Janette Dalay Robertson , Business Development Manager, will be attending the Milner Seminar May 2026 hosted by the Milner Therapeutics Institute at the Jeffrey Cheah Biomedical Centre , Cambridge, on 19 May 2026 from 4:00–5:00pm. The seminar will bring together experts from academia and industry to discuss innovation and collaboration in drug discovery and translational science. Pharmidex will also be exhibiting at the event. Janette will be near the café in the Jeffrey Cheah Biomedical Centre from 11am tomorrow, so if you would like to discuss drug discovery, preclinical development, bioanalysis, or potential collaborations, please feel free to stop by for a chat before the seminar begins. Looking forward to connecting with researchers, biotech innovators, and industry partners throughout the day!
May 18, 2026
We’re pleased to highlight Gaurang Patel and his extensive expertise in clinical and bioanalytical research. With more than 19 years of experience spanning analytical development, method validation, and regulatory-compliant environments, Gaurang brings deep scientific knowledge and operational leadership to every programme. His commitment to robust analytical methods, laboratory excellence, quality, and compliance continues to support the delivery of reliable, efficient, and audit-ready outcomes across complex research projects. At Pharmidex , we value the experience and dedication that help drive scientific progress and trusted partnerships.
More Posts